Category Archives: Genetics

Genetics

How Long Does It Take to Grow a Beard? Tips, Genetics, and More – Healthline

Facial hair, like scalp hair, grows in stages and understanding it may help you maximize your beard-growing potential.

A full beard can take 2 to 4 months to grow, as facial hair tends to grow between 0.3 and 0.5 millimeters (mm) every 24 hours. This works out to between one third and one half an inch per month.

Many factors can affect the growth of your beard, but there are some lifestyle strategies you can try to enhance your beard growth. Read on to learn more about what influences beard growth and if it can be influenced.

Once you stop shaving, you can expect facial hair to grow in stages. Hair may grow fuller and faster in certain areas, especially at first. Be patient, though, as this is a normal growth pattern for most guys.

Your ethnicity, age, genetics, and hormones not to mention various medical conditions can all affect whether your beard comes in faster or slower, or in all the places you desire.

If your beard seems to be taking a long time to grow in, one of the following factors may be at play.

You may remember guys in high school who seemed to have a full beard before they got their drivers license. Theyre the exception, not the rule.

Typically, full beard growth is possible starting at around age 18, but for many men, that time may not arrive until theyre 30. So, if youre not getting the beard growth you want, it may be because its not your time.

Certain ethnic groups tend to be more hirsute than others. Chinese men, for example, generally have less facial hair than white men, and men of Mediterranean descent generally have thicker beards.

Beyond your ethnic origins, your direct family traits have much to do with whether you can grow a full beard. Likewise, your genetics also determine the texture of your hair, your likelihood of going bald, and so forth.

For clues about your beards future, look to your male relatives. While theres no guarantee that a dad with a full beard will have a son who can pull off the same thing, hair patterns do tend to be hereditary.

Low levels of testosterone can make it more difficult to grow a beard. Talk with your doctor about taking supplements or trying testosterone therapy to help combat low testosterone.

If you want to grow your beard faster, there are a few strategies worth trying. Understand, however, that these tips may not work for everyone.

For general health, its recommended you have a balanced diet that includes fruits, vegetables, whole grains, and lean proteins, while avoiding processed food and added sugars.

For healthy hair growth, some key nutrients should have a place in your diet, including:

Too much stress and too little sleep can cause countless health problems, not to mention affect your beard growth.

Aim for 7 to 8 hours of sleep each night, and try strategies such as meditation or deep-breathing techniques to help de-stress.

Its not uncommon for guys to have thicker hair around their mouths and parts of their sideburns but a little less on their cheeks.

One way to help mask thinner (or zero) growth in those spots is to let the hair around them grow longer. You can hide those sparse spots a little with longer beard hair nearby.

Hair growth, whether its on your scalp or your face, is subject to many changes in your health.

Underlying medical conditions such as alopecia barbae or alopecia areata can cause hair loss from your beard or make it harder to grow a beard that isnt patchy or thin in places.

Alopecia areata is the more common condition. It occurs when the bodys immune system mistakenly attacks healthy hair follicles. When beard alopecia areata develops, men are usually middle-aged and hair loss is typically along the jawline.

Unusual conditions, such as prolactinoma a noncancerous tumor of the pituitary gland can also result in thin or missing facial hair.

Conversely, a noncancerous birthmark called Beckers nevus can sometimes cause excessive, coarse hair to form at the site of the birthmark.

The time it takes to grow a beard not to mention the look of the final product varies from person to person.

If youre trying to grow a full beard, plan on waiting a couple of months before you reach your goal. That means being patient and watching for signs of medical conditions that may affect your beard growth.

If youre concerned about a lack of beard growth, talk with your doctor or a dermatologist.

Read the original post:
How Long Does It Take to Grow a Beard? Tips, Genetics, and More - Healthline

Genetics

Help Me Understand Genetics: MedlinePlus Genetics

Genetics Home Reference has merged with MedlinePlus. Genetics Home Reference content now can be found in the "Genetics" section of MedlinePlus. Learn more

The resources on this site should not be used as a substitute for professional medical care or advice. Users with questions about a personal health condition should consult with a qualified healthcare professional.

View post:
Help Me Understand Genetics: MedlinePlus Genetics

Genetics

Genetic clues found for cognitive resilience to Alzheimer’s disease – National Institute on Aging

Three genetic variants may be associated with cognitive resilience in Alzheimers disease, according to the results of a large, genome-wide association study (GWAS). The study, funded in part by NIA, identified novel genetic variants, genes and biological pathways that are associated with cognitive resilience, or protection, from memory and thinking issues connected to Alzheimers disease despite the presence of neuropathology in the brain. Notably, the researchers did not see a connection between cognitive resilience and the genetic variations in the APOE gene that are associated with a higher risk of developing Alzheimers. The findings, published in Brain, provide new insights into the biology of cognitive resilience and may suggest new pathways and targets for development of Alzheimers treatments.

In the Alzheimers brain, abnormal levels of the naturally occurring protein, beta-amyloid, clump together to form plaques that collect between brain nerve cells and interfere with cell function. However, about 30% of people with significant amyloid plaque buildup do not develop the memory and thinking problems associated with Alzheimers disease. Researchers do not yet understand the biology behind this cognitive protection.

To learn more about genetic factors linked to cognitive resilience in Alzheimers disease, a team led by researchers at Vanderbilt University Medical Center conducted a GWAS study. GWAS is a research approach that connects DNA differences, called genetic variations, in a group of people with a certain disease or trait. Genetic variants may increase or decrease a persons risk of developing a particular disease.

Using DNA samples from a past clinical trial on Alzheimers disease and three studies on aging and cognition, the scientists scanned complete sets of DNA, or genomes, from more than 5,100 people. The study data included amyloid brain scans, autopsy, and cognition test results. For each person, the scientists compared the amount of amyloid plaque present and the cognitive test results to develop a measurement of resilience. Next, they looked for genetic patterns in the DNA of the people with high resilience scores.

Three genetic variants linked to cognitive resilience were identified near the ATP8B1 gene. This gene makes a protein that helps with liver metabolism, the process of breaking down fats to produce energy for the body. While more research is needed to determine whether the ATP8B1 gene is responsible for resilience, the researchers saw some signs to suggest that lower levels of this protein in the brain and liver may confer cognitive resilience.

The scientists also found that the level of resilience whether it was high or low was associated with genetic patterns for traits related to levels of education, cardiovascular disease risk, and some mental health disorders, such as obsessive-compulsive disorder. For example, people with a genetic risk for smoking and a younger age of starting smoking had lower cognitive resilience. Whereas people with genetic traits linked to higher levels of education showed higher cognitive resilience.

This study provides important new insights into the genetics and biological factors that protect some people from the cognitive symptoms of Alzheimers disease and may inform new approaches for treatments. While this was the largest GWAS study to date on cognitive resilience to Alzheimers disease, additional studies are needed with more racial and economic diversity to better reflect the general population.

This research was supported in part by NIA grants F31-AG059345, K01-AG049164, K24-AG046373, K99-AG061238, P30-AG010161, R01-AG003949, R01-AG017216, R01-AG018023, R01-AG025711, R01-AG032990, R01-AG034962, R01-AG046171, R01-AG056534, R01-AG057914, R01-AG059716, R01-AG15819, R01-AG17917, R01-NS100980 R13-AG030995, R21-AG05994, RF1-AG051550, P30-AG19610, P50-AG005136, P50-AG016574, U01-AG006576, U01-AG006786, U01-AG024904, U01-AG032984, U01-AG046139, U01-AG046152, U01-AG061356, U01-AG006781, U24-AG041689, and 3U01-AG024904-09S4.

These activities relate to NIA's AD+ADRD Research Implementation Milestone 2.S, Determine interrelationships among cerebro- and cardiovascular disease, VCID risk factors, aging, resilience, genetics, amyloid, tau, and neurodegeneration including along the life course.

Reference: Dumitrescu L, et al. Genetic variants and functional pathways associated with resilience to Alzheimer's disease. Brain. 2020;143(8):2561-2575. doi: 10.1093/brain/awaa209.

Read the original:
Genetic clues found for cognitive resilience to Alzheimer's disease - National Institute on Aging

Genetics

University is mapping the genetics of eating disorders to develop better treatments – yoursun.com

A new initiative at University of North Carolina at Chapel Hill is kicking off a genetic study of eating disorders that it says will be the largest of its kind.

If successful, the study, conducted by the Eating Disorders Genetic Initiative (EDGI), will be able to identify hundreds of genes that influence a person's likelihood of suffering from three prominent disorders: anorexia nervosa, bulimia nervosa and binge-eating disorder.

That knowledge could significantly improve the way those illnesses are treated, said Cynthia Bulik, a professor at the UNC School of Medicine and head of EDGI.

"It might help us with prediction and prevention in the future," Bulik said in a phone interview. "That is a direction we hope to go in help us identify those who are high risk."

Eating disorders affect a large number of people. About 9% of Americans, or 28.8 million, will have an eating disorder in their lifetime, according to the National Association of Anorexia Nervosa and Associated Disorders.

And that number could be increasing, as the coronavirus pandemic pushes the country into a mental health crisis as well. Bulik recently coauthored a study of individuals with eating disorders in the U.S. and the Netherlands that reported an increase in anxiety during the pandemic, which has disrupted the lives and routines of millions.

"We are clearly in the midst of a mental health pandemic," Bulik said. "The things (participants) talked about most was the lack of structure in their days ... (and) a lack of social support. Eating disorders thrive in isolation."

While there have been numerous psychiatric studies of eating disorders, the biologic underpinnings of the illness are still relatively unknown, and there are no medications to treat eating disorders

"Part of that is because we haven't understood the biology of eating disorders," she said.

EDGI is seeking 100,000 people across the world with a history of an eating disorder to volunteer as part of the genetic study. In the U.S., it is looking to reach 6,000 participants. In addition to genetics, EDGI will also survey participants from around the world to see how environmental factors influence the disorders.

Bulik said it will be important for EDGI to get a very diverse sample of volunteers. She hopes to complete the collection portion of the study by 2022.

The research is funded by the National Institute of Mental Health. The genetic samples will be collected via a saliva kit in the mail, and then be processed at a lab in Chapel Hill.

The study will build off a previous one that focused specifically on anorexia nervosa. Bulik said that study had transformational findings, identifying eight areas of the genome with significant associations with anorexia nervosa. Finding evidence for those associations, she said, helps reduce misunderstandings around the illness.

"These are serious illnesses with genetic bases, and we need to bust those myths about them being a choice," Bulik said. "One of the things that this research does is bust those myths. We can say with complete confidence that genes are involved."

That previous research only studied around 17,000 participants, and Bulik said the data would be much more reliable with a larger pool of volunteers.

By expanding the research to include other eating disorders, EDGI could determine if certain genetics predispose someone to multiple illnesses, or whether they all have unique causes.

"My gut says and preliminary information shows that there might be some shared genetic factors across all three disorders, but also unique genetic factors associated with them that decides the path (of treatment) you go down," she said. "There is not a clear demarcation between these disorders. People will toggle back and forth between anorexia and bulimia. They are not mutually exclusive."

EDGI is looking for participants who are 18 years or over and have, at any point in their lives, experienced anorexia nervosa, bulimia nervosa or binge-eating disorder. To volunteer or learn more, visit http://www.edgi.org.

Read more here:
University is mapping the genetics of eating disorders to develop better treatments - yoursun.com

Genetics

ICR Discovery Club gives members a virtual glimpse into the cancer genetics lab – The Institute of Cancer Research

Image: Dr Zsofia Kote-Jorai, who is a Senior Staff Scientist in Profesor Ros Eeles' lab explains to the Discovery Club how they perform genetic sequencing on tumour samples from men with prostate cancer

Members of the ICRs Discovery Clubwere given an exclusive insight into how researchers sample, process and analyse tumour cells in the lab, as part of the ICRs first virtual event for our donors.

Professor Ros Eeles, who leads the ICRs Oncogenetics Teamand is a world-leading expert in the genetics of prostate cancer, explained during a video event how she and her team analyse the DNA from thousands of men with and without prostate cancer to find genetic clues about the disease.

The ICR's Discovery Club offers a regular series of events for our donors to hear from some of our leading scientists and clinicians about their work. The event took place online for the first time instead of in person due to the coronavirus pandemic.

A video featuring members of Professor Eeles team showed how they are continuing their important work and making progress in studying cancer geneticsdespite the impact of coronavirus on research.

The virtual event was a chance for ICR researchers to share examples of cutting-edge research into the genetic causes of cancer with Discovery Club members from the comfort of their own home.

Professor Eeles explained that there are three billion letters that make up the human genome, our entire DNA structure in every cell, which was first read by scientists nearly 20 years ago.

This medical revolution means scientists can now identify genetic markers in our DNA linked to diseases like prostate cancer heralding a new era of personalised healthcare.

Finding the genetic markers for prostate canceris important because many men will never develop aggressive disease, so genetic screening can prevent unnecessary biopsies and scans in those that are likely to stay healthy, and pick up the disease sooner in men who need urgent treatment.

Discovery Club members watched a video showing Professor Eeles team preparing tumour samples in the lab, and explaining the steps needed to read their DNA.

This incredibly complex task requires sophisticated equipment and know-how, but ICR scientists are making great strides in uncovering genetic risk markers for prostate cancer.

Professor Ros Eeles has been has been instrumental in ensuring new discoveries in cancer genetics, immediately benefit patients. Learn about the work of Professor Eeles and the Oncogenetics Team.

Find out more

By comparing tiny changes across thousands of DNA sequences, scientists can pick out common variations in men that indicate an increased risk of prostate cancer.

Researchers like Professor Eeles and her team have identified 256 changes in DNA which increase the risk of men developing the disease, accounting for nearly half of all the inherited genetic risks for prostate cancer.

Professor Eeles is also identifying rare mutations that can lead to the most aggressive forms of prostate cancer.

Her team has found that men with BRCA2 mutations, a genetic fault also linked with breast cancer in women, were much more likely to develop prostate cancer than men without the mutation.

Professor Eeles is leading clinical trialslooking into whether regular DNA screening of men with mutations like BRCA2, could help diagnose prostate cancer earlier.

DNA screening could also give men more insight into their own health, helping them make decisions that could influence not only their cancer diagnosis, but their treatment too and which ultimately, could help them live longer and better lives.

We've lost many vital research hours to the coronavirus crisis but the need for our work continues to grow. Please help uskick-startour research to make up for lost time in discovering smarter, kinder and more effective cancer treatments, andto ensure cancer patients don't get left behind.

Support our work

ICR Chief Executive Professor Paul Workmansaid: It was great to hear from Professor Eeles today, whose research into cancer genetics is truly world leading. Her work is helping us to identify those people who have increased risk of prostate cancer, in order that we can detect and treat the disease sooner, and even potentially prevent men from developing prostate cancer in the first place. We know that cancer has not been self-isolating during this time, and we continue to publish major discoveries that will help us to make the discoveries that defeat cancer.

There is going to be an even greater need for cancer treatments and interventions as a result of Covid-19, and the support of our donors and their messages of encouragement is absolutely vital and appreciated. I cant thank you enough for your continued help and commitment to support us through these difficult times.

The Discovery Club is our high-value giving club whose members help us to drive forward our scientific strategy through philanthropic investment in key organisational priorities.

The events are an opportunity for members to hear from leading ICR scientists and clinicians about their work, and the ways that their support is making a difference.

It takes multidisciplinary teams of researchers and sophisticated data analysis to uncover the genetic causes of cancer, and we couldnt do it without your generous donations.

Your continued support helps push forward our vital research, ensuring that new discoveries in cancer genetics are brought rapidly into the clinic to benefit patients. If you would like to find out more,please contact Hannah Joyce, Deputy Director of Philanthropy.

More:
ICR Discovery Club gives members a virtual glimpse into the cancer genetics lab - The Institute of Cancer Research

Genetics

Breast Cancer Predictive Genetic Testing Market Industry Development, Growth Opportunities and Demand Analysis : Roche, Thermo Fisher Scientific -…

The globalBreast Cancer Predictive Genetic TestingMarket report offers a complete overview of the Breast Cancer Predictive Genetic Testing Market globally. It presents real data and statistics on the inclinations and improvements in global Breast Cancer Predictive Genetic Testing Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Breast Cancer Predictive Genetic Testing Market report elaborates the crucial data along with all important insights related to the current market status.The report also presents the historic, current and expected future market size, position, of the Breast Cancer Predictive Genetic Testing industry.The report further signifies the upcoming challenges, restraints and unique opportunities in the Breast Cancer Predictive Genetic Testing market. The report demonstrates the trends and technological advancement ongoing in the Breast Cancer Predictive Genetic Testing industry. In addition to the current inclinations over technologies and capabilities, the report also presents the variable structure of the market, worldwide. The study then describes the drivers and restraints for the market along with the impact they have on the demand over the forecast period. The report also highlights technological advancements and product developments that drive market needs. The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include: CompanyRoche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae

Get a Breast Cancer Predictive Genetic Testing Market Report Sample Copy @https://www.industryandresearch.com/report/Global-Breast-Cancer-Predictive-Genetic-Testing-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-2020-2025/201488#samplereport

The report has been curated after observing and studying various factors that determine regional growth such as economic,environmental, social,technological, and political status of the particular region. Analysts have studied the data of revenue, production,and manufacturers of each region.this section analyses region-wise revenue and volume for the forecast period of 2020 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region. The information presented in this report provides an overview of the latest trends and development plans, patterns, and policies observed in the global market. Moreover, the study provides an analysis of the latest events such as the technological advancements and the product launches and their consequences on the global Breast Cancer Predictive Genetic Testing market. Then it provides an overall competitive scenario of the market along with an advance approach to the market growth. The market is segmented by application with historical and projected market share and compounded annual growth rate. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The fundamental purpose of Breast Cancer Predictive Genetic Testing Market report is to provide a correct and strategic analysis of the industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market.The Global Breast Cancer Predictive Genetic Testing Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts,inputs from industry experts and industry participants across the value chain. The report also maps the qualitative impact of various market factors on market segments and geographies. The report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Breast Cancer Predictive Genetic Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Breast Cancer Predictive Genetic Testing market. The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks. Additionally, an expert team of researchers talks about key drivers and restraints that are influencing on the global market growth. Additionally, it offers detailed elaboration on risks, threats, and challenges faced by industries as well as various stakeholders.

Additionally, the report provides an extensive analysis of the key geographical regions of the industry. The regional analysis covers North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The report offers insightful information like production and consumption ratio, demand and supply, import and export ratio, and demand trends in each region. The report also covers a country-wise analysis of the segments and sub-segments of the market.

Market segment by Type, the product can be split into:High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes

Market segment by Application, split into:Hospitals, Clinics, Others

Reason to buy:* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects.* The report assists in realigning the business strategies by accentuate the Breast Cancer Predictive Genetic Testing business priorities.* The report throws light on the segment expected to dominate the Breast Cancer Predictive Genetic Testing industry and market.* Forecasts the regions expected to perceive ascension.* Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.* It offers the regional analysis of the Global Breast Cancer Predictive Genetic Testing Market along with the business profiles of several stakeholders.* The newest developments within the Breast Cancer Predictive Genetic Testing industry and details of the industry leaders along side their market share and methods.* Saves time on the entry level research as the report contains principal data concerning about growth, size, leading players and segments of the industry.* Save and cut time carrying out entry-level research by characterizing the growth, size, leading players and segments within the global Market.* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players.

Read Detailed Index report @https://www.industryandresearch.com/report/Global-Breast-Cancer-Predictive-Genetic-Testing-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-2020-2025/201488

The Breast Cancer Predictive Genetic Testing market factors described in this report are:Key Strategic Developments in Breast Cancer Predictive Genetic Testing market:The research includes the key strategic developments of the market, comprising R&D, M&A, agreements, new product launch, collaborations, partnerships, joint ventures, and regional growth of the key competitors functioning in the market on a global and regional scale.

Key Market Features in Breast Cancer Predictive Genetic Testing Market:The report assessed key market features, including revenue, capacity, price, capacity utilization rate, production rate, gross, production, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition to that, the study provides a comprehensive analysis of the key market factors and their latest trends, along with relevant market segments and sub-segments.

Analytical Tools:The Global Breast Cancer Predictive Genetic Testing Market report provides the rigorously studied and evaluated data of the top industry players and their scope in the market by means of several analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, SWOT analysis, and ROI analysis have been practiced reviewing the growth of the key players operating in the market.

The reports conclusion reveals the overall scope of the Global Breast Cancer Predictive Genetic Testing Market in terms of feasibility of investments in the various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the market in the near future. The Global Breast Cancer Predictive Genetic Testing Market is studied on the basis of pricing, dynamics of demand and supply, total volume produced, and the revenue generated by the products. The manufacturing is studied with regards to various contributors such as manufacturing plant distribution, industry production capacity, R & D. It also provides market evaluations including SWOT analysis, investments, return analysis, and growth, trend analysis. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, customers, research findings & conclusion, appendix & data source and Porters Five Forces Analysis.

In conclusion, the Breast Cancer Predictive Genetic Testing Market report is your trusted source for accessing research data that is expected to exponentially accelerate your business. This report provides information such as economic scenarios, benefits, limitations, trends, market growth rates, and figures. The SWOT analysis is also incorporated into the report along with the guess attainability survey and venture revenue survey.

Request customize:-If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @sales@industryandresearch.com

Visit link:
Breast Cancer Predictive Genetic Testing Market Industry Development, Growth Opportunities and Demand Analysis : Roche, Thermo Fisher Scientific -...

Genetics

Hunt on for future Covid mutations that cause treatments to lose potency – The Guardian

Scientists are to increase surveillance for new coronavirus mutations amid concerns that future strains of the virus could develop at least partial resistance to antibody treatments and Covid-19 vaccines.

There is no evidence that the mutations seen so far could help the virus evade vaccines or treatments now in development, but genetic analysis of circulating strains suggests that partially-resistant variants can emerge and spread among humans.

1 September 2020

Boris Johnson

Not only are we getting the pandemic under control, with deaths down and hospital admissions way, way down, but we will continue to tackle it, with local lockdowns and with our superlative test-and-trace system.

9 September 2020

Boris Johnson

NHS Test and Trace is doing a heroic job, and today most people get an in-person test result within 24 hours, and the median journey is under 10 miles if someone has to take a journey to get one [To Keir Starmer] We make the tough calls all he does is sit on the sidelines and carp.

9 September 2020

Boris Johnson

[On the moonshot proposal for mass, near-instant testing:] We are hopeful this approach will be widespread by the spring and, if everything comes together, it may be possible even for challenging sectors like theatres to have life much closer to normal before Christmas.

16 September 2020

Boris Johnson

We dont have enough testing capacity now because, in an ideal world, I would like to test absolutely everybody that wants a test immediately Yes, theres a long way to go, and we will work night and day to ensure that we get there.

17 September 2020

Matt Hancock

Of course there is a challenge in testing We have sent tests to all schools to make sure that they have tests available. But of course I also recognise the challenges in getting hold of tests Tests are available, even though it is a challenge to get hold of them.

In a paper drawn up for the governments Sage committee of experts, the UK Covid genomics consortium (Cog-UK) reports that a number of mutations have cropped up in the crucial spike protein which covers the virus like pins in a pin cushion and allows the pathogen to invade human cells.

Because many vaccines use the spike protein to generate immunity against the virus, mutations that subsequently change the spike can affect how well that immunity works.

Anything that affects the spike protein can potentially change how either natural immunity or vaccine-induced immunity responds to the virus, said Jeffrey Barrett, a geneticist and member of the consortium at the Sanger Institute near Cambridge.

The coronavirus that causes Covid-19 is genetically fairly stable, but it still acquires mutations, creating a multitude of lineages that geneticists can use to track the virus around the world and from outbreak to outbreak. By chance, some lineages will pick up mutations in the spike protein, a process called antigenic change. Many of these are likely to make the virus worse at spreading, but others may be neutral or even improve the viruss ability to infect.

The potential risk comes if the virus accumulates mutations in the spike protein that change it enough for antibody treatments and vaccines to lose their potency. This could be most problematic for so-called monoclonal antibody treatments, of the type given to Donald Trump, where patients are infused with a mixture of two different types of antibodies. Vaccines tend to induce a greater variety of antibodies, so even if some are ineffective, the rest should still target the virus.

The scientists describe how in the spring more than 500 people in Scotland contracted coronavirus with a spike mutation known as N439K. The mutant version vanished during lockdown, but later re-emerged in Romania, Norway, Switzerland, Ireland, Belgium, Germany, and is now circulating in the UK. The mutation, and at least half a dozen others, show that the spike protein can change without destroying the viruss ability to spread.

Scientists have shown already that coronavirus with the N439K mutation is resistant to at least one type of antibody that infected people can produce. The aim of the surveillance is to watch for future mutations that might, with time, make the virus resistant to a greater variety of antibodies.

The genetics consortium is setting up a group to monitor new and existing mutations to ensure that signs of potential resistance are spotted early. It is particularly important that surveillance of antigenic change is established in the lead up to the roll out of a vaccination program in the UK, since many of the vaccines under development target the spike protein, the paper states.

Paul Bieniasz, a virologist at Rockefeller University in New York, said it was important to monitor genetic variation in the viruss spike protein in order to anticipate potential problems ahead, rather than because there is any immediate threat from currently circulating variants.

The sporadic emergence of antibody resistance mutations, such as N439K, is one reason most antibody therapies rely on a cocktail of two antibodies. But Bieniasz said that depending on how widely those treatments are used, it will be important to monitor resistance to them in the same way that we monitor bacterial resistance to antibiotics, or HIV resistance to antiviral drugs.

A single mutation would be unlikely to render a Covid-19 vaccine impotent, he added, but as the virus evolves over the coming years, pharmaceutical firms might need to reformulate vaccines to take account of genetic changes that arise in the virus.

View original post here:
Hunt on for future Covid mutations that cause treatments to lose potency - The Guardian

Genetics

Cardiovascular Genetic Testing Market to Witness High Growth in Near Future and Competitive Analysis – PRnews Leader

The latest Report release from Database of Data Bridge Market Research has recently published the research Report TitledCardiovascular Genetic Testing Market. The study provides an overview of current statistics and future predictions of the Global Cardiovascular Genetic Testing Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry-validated market development data.

Cardiovascular genetic testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 4.01 billion by 2027 growing at a CAGR of 13.40% in the above-mentioned forecast period. An extensive array of employment of genetic experimentation in inherent disorders and oncology will prove advantageous for genetic testing business germination in the coming years.

Get Free Sample PDF (including COVID19 Impact Analysis) of Cardiovascular Genetic Testing Market[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiovascular-genetic-testing-market

Prominent Key Players Covered in the report:

Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, QIAGEN, Pathway Genomics, Pacific Biosciences of California, Inc, Natera, Inc., Myriad Genetics, Inc., ICON plc, Laboratory Corporation of America Luminex Corporation, IntegraGen., HTG Molecular Diagnostics, Inc. , Genomic Health, Inc., Admera Health, deCODE genetics among other domestic and global players.(Customization Available)

The GlobalCardiovascular Genetic Testing Marketresearch report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Cardiovascular Genetic Testing market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Cardiovascular Genetic Testing Market in each region. Various methodological tools are used to analyze the growth of the worldwide Cardiovascular Genetic Testing market.

Major Regions as Follows:

Global Cardiovascular Genetic Testing Market Research Reportalso provides the latest companies data and industry future trends, allowing you to identify the products and end users driving profits growth and productivity. The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, investigation and discussion of significant industry trends, market volume, market share estimates and profiles of the leading industry Players. Global Cardiovascular Genetic Testing Industry Market Research Report is providing exclusive vital statistics, information, data, trends and competitive landscape details. The Global Cardiovascular Genetic Testing market SWOT is provided for the international markets including progress trends, competitive landscape breakdown, and key in regions development status.

The Cardiovascular Genetic Testing report study has Three major sections which include:

Section 1:Market Introduction

This section deals with the Cardiovascular Genetic Testing market definition or the market along with the target audience of the market. Later in the chapters, the research methodologies and the market tools that were used for the market analysis is mentioned.

Section 2:Cardiovascular Genetic Testing Market DROC

The flow of this section is: Cardiovascular Genetic Testing market growth factors and limitations. In the later chapters, the Cardiovascular Genetic Testing market opportunities and challenges are described. All the points mentioned within the report are updated based on the COVID-19 situation.

Section 3:Conclusion and Observations

The last section of the report includes comments and observations by the research analysts and the market experts for the Cardiovascular Genetic Testing market.

Get Table Of Contents of This Premium Research For Free:https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiovascular-genetic-testing-market

How Does This Market Insights Help?

Key Pointers Covered in the Cardiovascular Genetic Testing Market Industry Trends and Forecast

Why choose us:

Market Dynamics:The Cardiovascular Genetic Testing report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

Strategic Points Covered in Table of Content of Global Cardiovascular Genetic Testing Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Cardiovascular Genetic Testing market

Chapter 2: Exclusive Summary the basic information about the Cardiovascular Genetic Testing Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Cardiovascular Genetic Testing

Chapter 4: Presenting the Cardiovascular Genetic Testing Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End-User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Cardiovascular Genetic Testing market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Cardiovascular Genetic Testing Market is a valuable source of guidance for individuals and companies in the decision framework.

Cardiovascular Genetic Testing Marketwill prove as a valuable source of guidance for professional clients like Tier 1, Tier 2, Tier 3 level managers, CEOs, CMOs, as well as the interested individual readers across the world. Vendor Landscape provide acts as key development and focus of above professional with common aim to lead the way of Cardiovascular Genetic Testing Market Worldwide

In conclusion, the Cardiovascular Genetic Testing Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cardiovascular-genetic-testing-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

View post:
Cardiovascular Genetic Testing Market to Witness High Growth in Near Future and Competitive Analysis - PRnews Leader

Genetics

Mount Sinai Doctors Elected to National Academy of Medicine for Contributions to Emergency Medicine and Translational Genetics – Newswise

Newswise (New York, NY October 19, 2020) Brendan G. Carr, MD, MA, MS, Chair of Emergency Medicine for the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, and Judy H. Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai and Director of The Charles Bronfman Institute for Personalized Medicine, have been elected to the National Academy of Medicine (NAM). Election to the NAM is considered one of the highest honors in health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service. With their election, Mount Sinai has 25 faculty members in the NAM.

The recognitions of Dr. Carr and Dr. Cho are well deserved for their groundbreaking contributions to emergency medicine and translational genetics, says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai. Dr. Carrs research has focused not only on improving the emergency care system for time-sensitive conditions such as trauma, stroke, cardiac arrest, and sepsis, but also on creating a more distributed and innovative approach to increasing access to acute care. Likewise, Dr. Cho is committed to improving care through personalized medicine and the understanding of each patients unique genes. She has enhanced genetic research, clinical implementation, and data platforms to ensure Mount Sinai remains at the forefront of genetic discoveries and implementation.

Emergency Medicine A leading voice in emergency medicine, Dr. Carr played a central role in coordinating Mount Sinais response to the COVID-19 pandemic. He has dedicated his career as an emergency medicine physician and health policy researcher to seamlessly combining research, policy, and practice to advance acute care delivery. Before joining Mount Sinai in February 2020, Dr. Carr held faculty positions at the Sidney Kimmel Medical College at Thomas Jefferson University and the Perelman School of Medicine at the University of Pennsylvania.

Outside academia, Dr. Carr has worked within the U.S. Department of Health and Human Services during both the current and previous administrations to improve trauma and emergency care services at the national level. His roles have included Senior Advisor and Director of the Emergency Care Coordination Center within the Office of the Assistant Secretary for Preparedness and Response, focusing on integrating the emergency care system into the broader health care delivery system. He previously supported the Indian Health Services initiatives to improve emergency care delivery, and worked with the Department of Veterans Affairs and the Department of Defense to integrate military and civilian health care response during disasters and public health emergencies. Dr. Carr has advised and supported major not-for-profit foundations, the World Health Organization, and the National Academy of Medicine.

He conducts health services research that connects disciplines including epidemiology, health care policy, business, economics, and health care delivery system science. His work has been continuously funded by the National Institutes of Health, the Centers for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. He has published and lectured widely on systems of care for trauma, stroke, cardiac arrest, and sepsis.

Ive spent my career focused on improving access to high-quality emergency care and am extremely humbled to be recognized by my peers with this honor. The recent COVID-19 surge reminded us of the importance of building robust systems that meet the needs of the communities that we serve. Im incredibly grateful for the opportunities Ive been given and the mentors that have helped to guide my career, says Dr. Carr. I am particularly grateful to be honored alongside my Mount Sinai colleague.

Translational Genetics Dr. Cho is an internationally recognized expert on the genetics and genomics of inflammatory bowel disease. As Dean of Translational Genetics, she leads strategic planning and integration of translational genetics research and care across school departments and institutes, with a focus on the rapid application of genetic and genomic discoveries to improve patient care. She also holds the Ward-Coleman Chair in Translational Genetics as well as professorships in Genetics and Genomic Sciences, and Medicine.

In 2013, Dr. Cho joined the Icahn School of Medicine faculty following appointments at the Yale University School of Medicine and the University of Chicago Pritzker School of Medicine. For the past five years, she has been Director of The Charles Bronfman Institute for Personalized Medicine and overseen the BioMe Biobank program, a pioneer in the movement toward diagnosis and classification of disease according to the patients molecular profile.

Science generally, and genetics especially, is a team sport; this recognition reflects many, many close collaborations over the years, says Dr. Cho. It is a privilege to try to advance science to help patients, and genetic discovery provides a particularly powerful means of prioritizing novel therapeutic targets.

Dr. Cho also leads an independent research program that is generously funded by the National Institutes of Health (NIH) and other extramural sources, and chairs the External Advisory Committee of the Wellcome Trust Centers for Human Genetics and Cellular Genetics. She has been Principal Investigator of the Data Coordinating Center for the Inflammatory Bowel Disease Genetics Consortium of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) since 2002 and chaired its Steering Committee for 16 years. Previously, she served on the American Society for Clinical Investigation Council and the NIDDK External Advisory Council, and chaired the Genetics of Health and Disease Study Section at the NIH. In 2014, Dr. Cho received the Crohns and Colitis Foundations Lifetime Achievement Award in Basic Science.

New members are elected to the NAM by current, active members through a selective process that recognizes leaders making major contributions to the advancement of the medical sciences, health care, and public health. Established in 1970 by the National Academy of Sciences, NAM is a national resource that provides independent, objective analysis and advice on health issues.

The elections of Dr. Carr and Dr. Cho bring Mount Sinais total membership in the prestigious group to 25 current and emeritus faculty members: Joseph D. Buxbaum, PhD Neil S. Calman, MD, MMS Dennis S. Charney, MD Kenneth L. Davis, MD Robert J. Desnick, MD, PhD Angela Diaz, MD, MPH Valentin Fuster, MD, PhD Bruce Gelb, MD Alison M. Goate, DPhil Kurt Hirschhorn, MD Yasmin L. Hurd, PhD Philip J. Landrigan, MD, MSc Helen S. Mayberg, MD Diane E. Meier, MD Eric J. Nestler, MD, PhD Maria Iandolo New, MD Peter Palese, PhD Ramon E. Parsons, MD, PhD Lynne D. Richardson, MD Hugh A. Sampson, MD Albert Siu, MD, MSPH Barbara G. Vickrey, MD, MPH Rachel Yehuda, PhD.

About the Mount Sinai Health System

The Mount Sinai Health System is New York Citys largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's Honor Roll of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in the country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Go here to read the rest:
Mount Sinai Doctors Elected to National Academy of Medicine for Contributions to Emergency Medicine and Translational Genetics - Newswise